News

Gustav Ullenhag, principal investigator of the LOKON003 trial presented the study at ESMO in Barcelona. In this study, LOAd703 TME gene engineering was used for patients with malignant melanoma in combination with PD-1/PD-L1 blockade.

Angelica Loskog, the CEO/CSO at Lokon presented data from the LOKON002 trial at ESMO. In this study, LOAd703 TME gene engineering was combined with chemotherapy in solid malignancies.

Sara Häggblad, Head of CMC and Titti Björnström, Head of QC/QA from Lokon Pharma will attend the viral vector process development summit on the 30-31th of August. Lokon Pharma will also have a presentation on “Setting out the right criteria for CDMO partners, and how to overcome capacity and availability for viral vector production for speed-to-patient”.